Multiple myeloma patients are often treated with immunomodulatory drugs, proteasome inhibitors or monoclonal antibodies until disease progression. Chronic therapy in combination with the underlying disease frequently results in severe humoral and cellular immunodeficiency, which often manifests in recurrent infections. Here we report on the clinical management and immunological data of one multiple myeloma patient diagnosed with COVID-19.
Recent Content
- Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide
- A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients
- Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study
- PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan
- T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma
- Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach
- Complex Pathological Femoral Fracture in a Multiple Myeloma Patient Undergoing Intertrochanteric Fixation: A Case Report
- A comparative analysis of transcriptomics of newly diagnosed multiple myeloma: exploring drug repurposing
- Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach
- Elotuzumab Efficacy May Suffer if Given After Daratumumab in Multiple Myeloma